Compare RVSN & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | VYNE |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 20.0M |
| IPO Year | N/A | 2017 |
| Metric | RVSN | VYNE |
|---|---|---|
| Price | $8.67 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.1K | ★ 215.1K |
| Earning Date | 03-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.46 | N/A |
| Revenue Next Year | $755.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.29 |
| 52 Week High | $9.39 | $1.98 |
| Indicator | RVSN | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 57.42 |
| Support Level | $0.31 | $0.56 |
| Resistance Level | $8.92 | $0.75 |
| Average True Range (ATR) | 0.69 | 0.03 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 65.74 | 75.42 |
Rail Vision Ltd is a development-stage technology company that is engaged in the design, development, and assembly of railway detection systems designed to solve the challenges in railway operational safety, efficiency, and predictive maintenance. Its railway detection systems include different types of cameras, including optics, visible light spectrum cameras (video), and thermal cameras that transmit data to a ruggedized onboard computer which is designed to be suitable for the rough environment of a train's locomotive. It has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.